- Home
- QNRX vs BJDX Comparison
QNRX vs BJDX Comparison
Compare QNRX & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- BJDX
- Stock Information
- Founded
- QNRX 2018
- BJDX 2015
- Country
- QNRX United States
- BJDX United States
- Employees
- QNRX N/A
- BJDX N/A
- Industry
- QNRX Medical/Dental Instruments
- BJDX Medical Specialities
- Sector
- QNRX Health Care
- BJDX Health Care
- Exchange
- QNRX Nasdaq
- BJDX Nasdaq
- Market Cap
- QNRX 2.1M
- BJDX 1.8M
- IPO Year
- QNRX N/A
- BJDX 2021
- Fundamental
- Price
- QNRX $0.62
- BJDX $0.07
- Analyst Decision
- QNRX Strong Buy
- BJDX
- Analyst Count
- QNRX 1
- BJDX 0
- Target Price
- QNRX $4.00
- BJDX N/A
- AVG Volume (30 Days)
- QNRX 486.4K
- BJDX 48.0M
- Earning Date
- QNRX 11-07-2024
- BJDX 11-07-2024
- Dividend Yield
- QNRX N/A
- BJDX N/A
- EPS Growth
- QNRX N/A
- BJDX N/A
- EPS
- QNRX N/A
- BJDX N/A
- Revenue
- QNRX N/A
- BJDX N/A
- Revenue This Year
- QNRX N/A
- BJDX N/A
- Revenue Next Year
- QNRX N/A
- BJDX N/A
- P/E Ratio
- QNRX N/A
- BJDX N/A
- Revenue Growth
- QNRX N/A
- BJDX N/A
- 52 Week Low
- QNRX $0.48
- BJDX $0.07
- 52 Week High
- QNRX $6.18
- BJDX $31.28
- Technical
- Relative Strength Index (RSI)
- QNRX 43.57
- BJDX 36.97
- Support Level
- QNRX $0.60
- BJDX $0.08
- Resistance Level
- QNRX $0.77
- BJDX $0.14
- Average True Range (ATR)
- QNRX 0.07
- BJDX 0.03
- MACD
- QNRX -0.02
- BJDX 0.00
- Stochastic Oscillator
- QNRX 12.98
- BJDX 0.54
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.